TriangleLUTATHERA (Lutetium Lu 177 dotatate) (NCT05278208)
LUTATHERA (Lutetium Lu 177 dotatate) trial for High Grade Glioma (NCT05278208). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
When a child's brain tumor returns after surgery, radiation, and chemotherapy, there is rarely a standard next step.
The idea: borrow a radioactive drug approved for adult gut tumors, and let it find brain tumors that share the same receptor.
Lutathera is a small peptide carrying lutetium-177. It binds a somatostatin receptor that most medulloblastomas, and some gliomas, ependymomas, and meningiomas, carry on their surface. A PET scan shows whether the tumor takes it up. If so, the drug goes in by vein every eight weeks, up to four times, and delivers radiation from inside the tumor.
Margot Lazow leads the trial from Nationwide Children's, with Philadelphia, Cincinnati, and Colorado, for ages four to thirty-nine. Safety first. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.